Reaction

Breast Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,019 reports · 55 co-occurring drugs

As of the last recalculation, Breast Disorder appears in 2,019 FAERS reports alongside 55 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 60.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ado-Trastuzumab Emtansine	48	60.1	60.4
Pertuzumab	62	24.2	24.3
Zonisamide	27	19.1	19.1
Alendronate Sodium	171	19.0	19.0
Atazanavir	25	18.1	18.2
Darunavir	24	16.5	16.6
Ribociclib	49	16.4	16.4
Nevirapine	14	16.1	16.1
Conjugated Estrogens And Medroxyprogesterone Acetate	31	13.7	13.8
Trastuzumab	85	13.3	13.3
Human Immunoglobulin G	25	12.6	12.6
Anastrozole Tablets	24	11.7	11.7
Heparin Sodium	15	11.3	11.3
Conjugated Estrogens	60	10.9	10.9
Letrozole	63	10.9	10.9
Estrogens, Conjugated	60	10.7	10.7
Risperidone	130	10.7	10.7
Alpelisib	9	10.7	10.7
Letrozole Tablets	48	10.5	10.5
Tramadol Hydrochloride	34	9.5	9.5
Lapatinib	14	9.4	9.4
Raloxifene Hydrochloride	13	9.2	9.2
Anastrozole	32	9.1	9.1
Exemestane	18	8.7	8.7
Ritonavir	24	8.6	8.6
Theophylline Anhydrous	10	8.4	8.4
Theophylline	9	8.1	8.1
Valproate Sodium	16	8.0	8.0
Fulvestrant	25	7.9	7.9
Quinapril Hydrochloride	6	7.9	7.9
Canagliflozin	22	7.7	7.7
Medroxyprogesterone Acetate	34	7.1	7.1
Goserelin	9	6.9	6.9
Estradiol	56	6.8	6.8
Capecitabine	59	6.8	6.8
Paclitaxel (Aibumin-Bound)	50	6.4	6.4
Estradiol Gel 0.1%	27	6.2	6.2
Estradiol Transdermal	27	6.2	6.2
Paliperidone	14	6.2	6.2
Paclitaxel	54	5.7	5.8
Mirabegron	21	5.6	5.6
Etonogestrel And Ethinyl Estradiol	11	5.1	5.1
Abatacept	64	4.9	4.9
Apixaban	30	4.7	4.7
Gemcitabine	17	4.5	4.5
Botulinum Toxin Type A	5	4.2	4.2
Glecaprevir And Pibrentasvir	4	3.8	3.8
Atezolizumab	14	3.7	3.7
Palbociclib	33	3.6	3.6
Paliperidone Palmitate	11	3.5	3.5
Ocrelizumab	20	3.3	3.3
Denosumab	64	3.3	3.3
Alirocumab	5	2.1	2.1
Levonorgestrel	38	2.0	2.0
Etonogestrel	6	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.